Doctors warn against off-label use of new Alzheimer's drug for cerebral amyloid angiopathy

(Massachusetts General Hospital) There is no clinical evidence that the monoclonal antibody aducanumab is beneficial to patients with cerebral amyloid angiopathy, according to a Massachusetts General Hospital neurologist and other officers with the International Cerebral Amyloid Angiography Association. In a letter in The Lancet Neurology, the group cited concerns over safety and efficacy in recommending that aducanumab not be prescribed off-label by physicians for the treatment of cerebral amyl...